Shanghai, China, September 05, 2024 – MicroPort® CardioFlow Medtech Corporation (“the Company”) recently announced that its subsidiary, MicroPort® CardioAdvent, has expedited the initial clinical applications of its independently developed AnchorMan™ Left Atrial Appendage（the “LAA”) Closure System（the “AnchorMan™ LAAC System”) following its market launch.
Approved for market release by the National Medical Products Administration (NMPA) in January 2024, AnchorMan™ is currently the only semi-closed LAAC device available in China. To date, it has been successfully implanted in 41 cases across 12 provinces, demonstrating its growing adoption in clinical practice. Initial clinical applications have shown outstanding outcomes, with postoperative imaging for all patients indicating complete occlusion and remarkable effectiveness.
The AnchorMan™ LAAC System offers a unique combination of the benefits of both traditional open and closed LAAC devices. Its semi-closed structure, formed by the 12 “3D folding” units and the frame, combines the strengths of open and closed closure device, addressing the clinical challenge of deep sheath placement in traditional plug-in closure devices while achieving stable anchoring. The rounded, soft distal end could minimize damage to LAA tissue, while the dense NiTi alloy frame design ensures tight conformity to the LAA anatomy, providing superior sealing performance. Additionally, two deployment models of advancement and unsheathe are available, offering physicians more flexibility during procedures.
Since its launch, the AnchorMan™ LAAC System has received significant recognition at various authoritative academic conferences in the cardiovascular field，garnering high praise for its robust performance, exceptional clinical data, and positive feedback from both physicians and patients. The rapid adoption of the first batch of implants highlights the system’s accelerated domestic commercialization, which will further contribute to increasing the Company’s revenue and boosting its profitability. Concurrently, the global strategy for the AnchorMan™ LAAC System is progressing steadily. The CE registration application was officially submitted in December 2023, with EU CE certification anticipated by 2025.
Looking ahead, with a focus on product development and technological innovation, the Company will continue to expand its portfolio of interventional therapy products for structural heart disease, providing high-quality, accessible, and comprehensive solutions to patients worldwide.
About MicroPort® CardioFlow
Founded in 2015, MicroPort® CardioFlow (MicroPort® CardioFlow Medtech Corporation; HKEX: 02160) is a leading medical device company focusing on research, development and commercialization of innovative transcatheter and surgical solutions for structural heart disease.
MicroPort® CardioFlow's self-developed transcatheter aortic valve implantation series products are successfully used in more than 600 core hospitals worldwide. In addition, MicroPort® CardioFlow has established a strategic Research and Development pipeline covering TAVI (transcatheter aortic valve treatment) products, left atrial appendage closure systems, transcatheter mitral valve treatment products, transcatheter tricuspid valve treatment products, and surgical accessories through in-house development and collaboration with global partners. MicroPort® CardioFlow is committed to providing total solutions for structural heart diseases, delivering high quality therapeutic solutions to patients and physicians across the globe.
More information is available at www.en.cardioflowmedtech.com